Literature DB >> 9624725

A survey of bloodborne viruses and associated risk behaviours in Greek prisons.

M Malliori1, V Sypsa, M Psichogiou, G Touloumi, A Skoutelis, N Tassopoulos, A Hatzakis, C Stefanis.   

Abstract

AIMS: To determine HIV and hepatitis infection prevalence and correlates with risk behaviour.
DESIGN: Cross-sectional study: voluntary, anonymous HIV, hepatitis (HCV, HBV and HDV) surveillance and questionnaire on risk factors.
SETTING: Korydallos Prison, Athens and Ag. Stefanos Prison, Patra, Greece. PARTICIPANTS: Of 544 drug users imprisoned for drug related offences, all completed the questionnaire and 533 blood samples were collected. MEASUREMENTS: HIV (by anti-HIV-1), HCV (by anti-HCV), HBV (by anti-HBc, HBsAg) and HDV (by anti-HDV) prevalence. Data on demography, legal status, drug use, sharing of injecting equipment.
FINDINGS: Of the 544 drug users, 375 (68.9%) had injected drugs (IDUs) at some time, 35% of whom had injected whilst in that prison. Of the 533 blood samples tested, one was positive for anti-HIV-1 (0.19%), 310 for anti-HCV (58.2%), 306/531 (57.6%) for anti-HBc, 34/527 (6.5%) for HBsAg and 12/527 (2.3%) for anti-HDV. Prevalence rates for IDUs only were 0.27% for HIV-1, 80.6% for hepatitis C, 62.7% for hepatitis B and 3.3% for hepatitis D. Ninety-two per cent of IDUs injecting in prison shared needles, indicating that IDUs inject less but share more during incarceration. Multiple logistic regression revealed needle-sharing as the most important risk factor for HCV infection in IDUs. Prior knowledge of a positive hepatitis result did not appear to inhibit IDUs from practising risky behaviours in prison.
CONCLUSIONS: The epidemic of hepatitis B and C among imprisoned IDUs identified by this study constitutes a major public health problem. Prevention programmes, such as counselling, HBV vaccination, community-based methadone maintenance treatment and syringe exchange schemes, are necessary in order to prevent a further spread.

Entities:  

Mesh:

Year:  1998        PMID: 9624725     DOI: 10.1046/j.1360-0443.1998.9322438.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  19 in total

1.  Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour.

Authors:  Jacob M Izenberg; Chethan Bachireddy; Jeffrey A Wickersham; Michael Soule; Tetiana Kiriazova; Sergii Dvoriak; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2014-02-28

2.  Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users.

Authors:  H Thiede; M Romero; K Bordelon; H Hagan; C S Murrill
Journal:  J Urban Health       Date:  2001-06       Impact factor: 3.671

3.  Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation.

Authors:  Prem H Thurairajah; Doha Hegazy; Andrew Demaine; Edward R Kaminski; Matthew E Cramp
Journal:  J Infect Dis       Date:  2011-03-15       Impact factor: 5.226

4.  Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study.

Authors:  M Raptopoulou; G Touloumi; D Tzourmakliotis; G Nikolopoulou; M Dimopoulou; G Giannoulis; T Vasiliadis; A Skoutelis; O Anagnostou; G Hatzis; S Manolakopoulos
Journal:  Hippokratia       Date:  2011-01       Impact factor: 0.471

5.  Prevalence and incidence of bloodborne viral infections among Danish prisoners.

Authors:  P B Christensen; H B Krarup; H G Niesters; H Norder; J Georgsen
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

6.  Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey.

Authors:  S Allwright; F Bradley; J Long; J Barry; L Thornton; J V Parry
Journal:  BMJ       Date:  2000-07-08

7.  Prisoners are at risk for hepatitis C transmission.

Authors:  Tony Butler; Azar Kariminia; Michael Levy; John Kaldor
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

8.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais; Corina Lelutiu-Weinberger
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

9.  Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees.

Authors:  V Sypsa; E Hadjipaschali; A Hatzakis
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

10.  Incarceration experiences among a community-recruited sample of injection drug users in Bangkok, Thailand.

Authors:  Kanna Hayashi; M-J Milloy; Nadia Fairbairn; Karyn Kaplan; Paisan Suwannawong; Calvin Lai; Evan Wood; Thomas Kerr
Journal:  BMC Public Health       Date:  2009-12-30       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.